表纸
市场调查报告书

全球白血病药物市场:价格,专利,剂量,临床试验(2025年)

Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025

出版商 PNS Pharma 商品编码 948447
出版日期 内容资讯 英文 1740 Pages
商品交期: 最快1-2个工作天内
价格
全球白血病药物市场:价格,专利,剂量,临床试验(2025年) Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025
出版日期: 2020年07月10日内容资讯: 英文 1740 Pages
简介

预计在未来六年中,全球白血病药物市场将增长60%,到2025年将超过220亿美元。当前,有633种管道产品正在临床试验中,市场上有70多种类型。

该报告分析了世界范围内白血病治疗剂的临床试验现状和市场趋势。我们将收集诸如市场趋势展望,主要管道产品概述和临床试验进展,主要市场促销和限制因素,主要公司概况和临床试验趋势等信息。

内容

第1章白血病:简介

  • 概述
  • 历史:白血病的首次描述和起源

第2章药品市场中相关的白血病药物

第3章非处方药及其对白血病治疗市场的影响

第4章白血病药物市场增长趋势:化学治疗药物

  • 概述
  • 化疗药物对白血病癌细胞的作用机制

第5章免疫疗法候补药:白血病药物市场的有前途的属性

  • 概述
  • 免疫疗法对白血病细胞的作用机理

第6章小分子抗癌药:对白血病药物市场的促进生长作用

  • 概述
  • 小分子抗癌药治疗白血病的作用机理

第7章骨髓移植:对白血病治疗市场的影响

  • 概述
  • 白血病患者骨髓移植的作用机制

第8章放射疗法:白血病治疗对市场增长的影响

  • 概述
  • 放射疗法治疗白血病的作用机理

第9章白血病治疗剂的持续临床研究与开发

第10章考虑企业联盟和合作开发白血病药物

第11章全球白血病药物市场概述

第12章区域性白血病药物市场分析

  • 美国
  • 欧洲
  • 亚洲
  • 中东/非洲

第13章白血病治疗剂的全球临床试验概述

  • 按阶段
  • 按国家
  • 按药品类别
  • 由公司/医疗机构
  • 按患者细分

第14章用于白血病的抗肿瘤药物:可获得性/剂量/价格分析

  • Azacitidine(Vidaza)
  • Venetoclax(Venclexta)
  • Enasidenib(Idhifa)
  • Tretinoin(Vesanoid)
  • Histamine Dihydrochloride Injection(Ceplene)
  • Ubenimix (Bestatin)
  • Arsenic Trioxide (Trisenox)
  • Tamibarotene(Amnolake)
  • Amsacrine(Amsa PD/Amekrin)
  • Immune Globulin(Gammagard Liquid,Gammagard S/D,Cuvitru,HyQvia)
  • Crisantaspase(Erwinase)
  • Pegaspargase (Oncaspar)
  • Calaspargase Pegol (Asparlas)
  • Asparaginase (Elspar/Kidrolase/Leunase)
  • Sobuzoxane(Perazolin)

第15章白血病多激□抑制剂:可用性,剂量,价格分析

  • 吉利替尼(Xospata)

第16章用于白血病的酪氨酸激□抑制剂:可用性,剂量,价格分析

  • Bosutinib (Bosulif)
  • Dasatinib(Sprycel)
  • Ponatinib(Iclusig)
  • Nilotinib(Tasigna)
  • Quizartinib(Vanflyta)
  • Radotinib(Supect)
  • Imatinib(Gleevec)

第17章白血病抗代谢药物:可用性,剂量,价格分析

  • Cytarabine/Daunorubicin (Vyxeos)
  • Ivosidenib (Tibsovo)
  • Rituxan Hysera(hyaluronidase/rituximab)

第18章用于白血病的抗肿瘤联合药物:可获得性/剂量/价格分析

  • Cladribine(Mavenclad/leusstatin)
  • Clofarabine(Clolar)
  • Mercaptopurine Oral Suspension(Purixan)
  • Methotrexate Oral Solution(Xatmep)
  • Decitabine (Decogen)
  • Nelarabine(Arranon)
  • Fludarabin(Fludara/Oforta)
  • Methotrexate

第19章白血病抗癌抗生素:可获得性,剂量,价格分析

  • Pentostatin(Nipent)
  • Mitoxantrone (Novantrone)
  • Idarubicin (Idamycin)

第20章磷酸肌醇3-激□抑制剂:可用性,剂量,价格分析

  • Duvelive(Copiktra)
  • Idelalisib(Zydelig)

第21章白血病烷基化剂:可获得性,剂量,价格分析

  • Bendamustine (Treanda/Belrapzo/Bendeka)
  • Cyclophosphamide
  • Dianhydrogalactitol(DAG for Injection)

第22章白血病的布鲁顿酪氨酸激□(BTK)抑制剂:可得性,剂量,价格分析

  • Ibrutinib (Imbruvica)

第23章白血病单克隆抗体:可用性,剂量,价格分析

  • Inotuzumab ozogamicin(Besponsa)
  • Gemtuzumab ozogamicin(Mylotarg)
  • Ofatumumab(Arzerra)
  • Gajiba(Obinutuzumab)
  • MabThera/Rituxan (Rituximab)
  • Blinatumomab(Blincyto)
  • Lumoxiti (Moxetumomab Pas de Tox)
  • Poteligeo(Mogamulizumab)
  • Rituximab Biosimilar(Truxima)
  • Rituximab Biosimilar(Ruxience)
  • Rituximab Biosimilar(Rixathon)
  • Rituximab Biosimilar- Acellbia
  • Rituximab Biosimilar - Maball
  • Rituximab Biosimilar - Mabtus
  • Rituximab Biosimilar - Zytux
  • Alemtuzumab(Campath)

第24章用于白血病的T细胞疗法:可用性,剂量,价格分析

  • Chisagen Lecroixel(Kymriah)
  • Nalotimagene Carmaleucel(Zalmoxis)

第25章白血病抗有丝分裂药:可用性,剂量,价格分析

  • Vincristine Liposomal(Marqibo)

第26章白血病抗肿瘤干扰素:可获得性,剂量,价格分析

  • Interferon Alpha-2b(Intron A)
  • Interferon Alpha-2a(Roferon-A/Veldona)
  • Interferon Alpha(Multiferon)

第27章白血病药物临床试验管道:按公司,按症状,按阶段(h4)
  • 未知
  • 研究阶段
  • 临床前
  • 临床
  • 阶段0
  • 第I阶段
  • I/II期
  • 第II阶段
  • 第II/第III阶段
  • 第III阶段
  • 预认证
  • 已验证

第28章全球上市的白血病药物:临床考虑因素

第29章。全球白血病药物市场的动态

  • 促进市场增长的因素
  • 市场增长的挑战:世界水平

第30章全球白血病药物市场的未来分析

第31章竞争环境

  • AbbVie Inc
  • Bristol-Myers Squibb
  • Amgen
  • Genzyme Corporation
  • Pfizer
  • GlaxoSmithKline Plc
  • Novartis International AG
  • Teva Pharmaceuticals
  • Takeda Pharmaceuticals
  • Piramal Pharma Solutions
目录

"Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025" Report Highlights:

  • Global Leukemia Drug Market Opportunity: More Than US$ 22 Billion by 2025
  • Comprehensive Insight on Leukemia Drug Clinical Trials: 633 Drugs
  • Leukemia Drug Clinical Pipeline Insight by Company, Drug Class, Patent
  • Comprehensive Clinical Insight on Marketed Leukemia Drug: 77 Drugs
  • Marketed Leukemia Drug Insight by Drug Class: Availability, Dosage & Price Analysis
  • Global Drug Development Partnerships & Collaboration Insight

"Global Leukemia Drug Market, Drug Price, Patent, Dosage & Clinical Trials Insight 2025" offers comprehensive insights on the various clinical and non-clinical parameters responsible for growth of global leukemia drug market. The emergence of new technological innovations in clinical research and drug development methodologies has led to the desired thrust to the market in recent years. This in-depth study enables its readers to identify and let them aware about the ongoing clinical trials, marketed drug dosage and price analysis, market advancements and associated commercial opportunities offered in the form of detailed analysis and graphical information presented in the report. As per report findings the market is expected to witness almost 60% absolute growth in next 6 years (2020-2025) and is estimated to surpass US$ 22 Billion by 2025.

The market is currently anticipated to be growth driven by many potential therapies as well as hundreds of ongoing clinical trials. There are more than 600 drugs in clinical trials and more than 70 drugs are commercially available in the market. The various advantages that are further adjoined by the market: private and public funding, innovative technologies and advancement such as artificial intelligence are classified as fundamentals for transforming the market status in a small period of time. The market has been more concentrated towards promoting the entry of small pharmaceutical companies into it such that it will seamlessly reduce the efforts given by single or few pharmaceutical companies involved in it.

The primary aim of the market is to develop novel patient centric candidates and collection of data at global level in order to predict the future course of action for the market. This is getting targeted to level down the potential challenges that could come across in the future. The insights of the market with respect to latest trends and challenges provides an overview about the substantial growth of the market as factors such as strong clinical pipeline, ongoing partnerships and collaborations and involvement of elite research and educational centers are powered together in order to fuel the leukemia therapy development. The market is collectively boosted by the presence of digital technology as well as advanced analytics for improving the clinical research and development productivity.

The ongoing clinical trials driven by revolutionized research based work have started offering dynamic opportunities towards patient centric approach in the market. It is estimated that the adoption of some changes in the regulatory system will expand the market in the next decade. The same is also accompanied by the emergence of technological innovations which has apparently resulted in the development of novel immunotherapy for the patients. All the advantages that are associated with the market have made it more efficient as well as effective. Currently, a wide range of anticancer drugs are used for the management of leukemia including Kinase inhibitors, BTK Inhibitors, monoclonal antibodies, antimetabolites, T-cell therapy, Interferons etc. while many new therapeutics are under investigation. Further, orphan drug designation and fast track approvals are also granted to many drugs by FDA, which is indicating a huge market potential of this segment in upcoming years.

Many leading pharmaceutical companies are adopting key strategies including acquisitions and new product launches, which generates new opportunities in leukemia drug market. In addition to this, the investments related to research and development of novel cancer therapeutics is increasing rapidly and many new drugs targeting leukemia are in late stage of clinical trial. Approval of these new drugs is expected in upcoming 1 to 2 years, which take this market to the next level. As per report findings, all the crucial trends that are associated with the leukemia market are making a huge impact on the overall development of the leukemia drugs. It is speeding the way of launch of novel and much needed medicines for the patients who are suffering from leukemia. Steps from incorporation of smart technologies in research to development of novel therapies for leukemia are pointing towards a more efficient as well as cost-effective solutions for millions of patients at global level.

Table of Contents

1. Introduction to Leukemia

  • 1.1 Overview
  • 1.2 History: Initial Description & Origin of Leukemia

2. Relevance of Leukemia Therapeutics in Pharmaceutical Market

3. Commercially Available Treatments & its Impact on the Global Leukemia Therapeutics Market

4. Leukemia Therapeutics Market Growth with Chemotherapy Drugs

  • 4.1 Overview
  • 4.2 Mechanism of Action of Chemotherapy Drugs towards Leukemia Cancer Cells

5. Immunotherapy Candidates Promising Attribute towards Global Leukemia Therapeutics Market

  • 5.1 Overview
  • 5.2 Mechanism of Action of Immunotherapy against Leukemia Cells

6. Small Molecule Cancer Drugs Evolving Global Leukemia Therapeutics Market

  • 6.1 Overview
  • 6.2 Mechanism of Action of Small Molecule Cancer Drugs towards Leukemia Treatment

7. Global Impact of Bone Marrow Transplantation on Leukemia Therapeutics Market

  • 7.1 Overview
  • 7.2 Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients

8. Radiation Therapy Impact on the Global Leukemia Therapeutics Market Growth

  • 8.1 Overview
  • 8.2 Mechanism of Action of Radiation Therapy for Leukemia Treatment

9. Ongoing Clinical Research Development for Leukemia Therapeutics

  • 9.1 UCLA to Combine Two Therapies to Leukemia Treatment Platform Available
  • 9.2 CAR-T Cell Trials for Common Leukemia & Lymphoma Types led by UCLA
  • 9.3 LILRB4, A New Potential Target for Leukemia Focused by UT Southwestern Researchers
  • 9.4 Phase Ib/II Trial Result for IDH1-Mutated Acute Myeloid Leukemia by University of Texas M. D. Anderson Cancer Center
  • 9.5 CAR-NK Cell Therapy for Clinical Trials Results for chronic lymphocytic leukemia by The University of Texas MD Anderson Cancer Center
  • 9.6 Takeda's Phase II Trial of Pevonedistat & Azacitidine in Patients with Leukemia

10. Global Partnerships & Collaboration Insights for Development of Leukemia Therapeutics

  • 10.1 Piramal Pharma Solutions & BerGenBio to Undergo FDA Fast Track Leukemia Treatment Development
  • 10.2 Pascal Biosciences and Y-Biologics to Develop Bispecific Antibody for Leukemia Treatment
  • 10.3 Daiichi Sankyo & MD Anderson Collaboration for Accelerated Development of Acute Myeloid Leukemia Therapies
  • 10.4 Merck & Harvard to Undergo Collaboration for Developing Small Molecule Drugs for Acute Myeloid Leukemia
  • 10.5 JZP-458 Pivotal Phase 2/3 for Acute Lymphoblastic Leukemia Study Initiation Announcement by Jazz Pharmaceuticals

11. Global Leukemia Therapeutics Market Market Overview

12. Regional Leukemia Therapeutics Market Analysis

  • 12.1 US
  • 12.2 European Union
  • 12.3 Asia
  • 12.4 Middle East & Africa

13. Global Leukemia Drug clinical Trials Overview

  • 13.1 By Phase
  • 13.2 By Country
  • 13.3 By Drug Class
  • 13.4 By Company/Clinic
  • 13.5 By Patient Segment

14. Antineoplastic Drugs for Leukemia - Availability, Dosage & Price Analysis

  • 14.1 Azacitidine (Vidaza)
  • 14.2 Venetoclax (Venclexta)
  • 14.3 Enasidenib (Idhifa)
  • 14.4 Tretinoin (Vesanoid)
  • 14.5 Histamine Dihydrochloride Injection (Ceplene)
  • 14.6 Ubenimix (Bestatin)
  • 14.7 Arsenic Trioxide (Trisenox)
  • 14.8 Tamibarotene (Amnolake)
  • 14.9 Amsacrine (Amsa PD/Amekrin)
  • 14.10 Immune Globulin (Gammagard Liquid, Gammagard S/D, Cuvitru & HyQvia)
  • 14.11 Crisantaspase (Erwinase)
  • 14.12 Pegaspargase (Oncaspar)
  • 14.13 Calaspargase Pegol (Asparlas)
  • 14.14 Asparaginase (Elspar/Kidrolase/Leunase)
  • 14.15 Sobuzoxane (Perazolin)

15. MultiKinase Inhibitor Drugs for Leukemia - Availability, Dosage, & Price Analysis 15.1 Gilteritinib (Xospata)

16. Tyrosine Kinase Inhibitors for Leukemia - Availability, Dosage, & Price Analysis 16.1 Bosutinib (Bosulif) 16.2 Dasatinib (Sprycel) 16.3 Ponatinib (Iclusig) 16.4 Nilotinib (Tasigna) 16.5 Quizartinib (Vanflyta) 16.6 Radotinib (Supect) 16.7 Imatinib (Gleevec)

17. Combinational Antineoplastic Drugs for Leukemia - Availability, Dosage & Price Analysis 17.1 Cytarabine/Daunorubicin (Vyxeos) 17.2 Ivosidenib (Tibsovo) 17.3 Rituxan Hycela (hyaluronidase/rituximab)

18. Antimetabolites for Leukemia - Availability, Dosage & Price Analysis 18.1 Cladribine (Mavenclad/Leustatin) 18.2 Clofarabine (Clolar) 18.3 Mercaptopurine Oral Suspension (Purixan) 18.4 Methotrexate Oral Solution (Xatmep) 18.5 Decitabine (Decogen) 18.6 Nelarabine (Arranon) 18.7 Fludarabin (Fludara/Oforta) 18.8 Methotrexate

19. Anticancer Antibiotics for Leukemia - Availability, Dosage & Price Analysis 19.1 Pentostatin (Nipent) 19.2 Mitoxantrone (Novantrone) 19.3 Idarubicin (Idamycin)

20. Phosphoinositide 3-Kinase Inhibitors - Availability, Dosage & Price Analysis 20.1 Duvelisib (Copiktra) 20.2 Idelalisib (Zydelig)

21. Alkylating Agents for Leukemia - Availability, Dosage & Price Analysis 21.1 Bendamustine (Treanda/Belrapzo/Bendeka) 21.2 Cyclophosphamide 21.3 Dianhydrogalactitol (DAG for Injection)

22. Bruton Tyrosine Kinase (BTK) Inhibitors for Leukemia - Availability, Dosage, & Price Analysis 22.1 Ibrutinib (Imbruvica)

23. Monoclonal Antibodies for Leukemia - Availability, Dosage, & Price Analysis 23.1 Inotuzumab ozogamicin (Besponsa) 23.2 Gemtuzumab ozogamicin (Mylotarg) 23.3 Ofatumumab (Arzerra) 23.4 Gazyva (Obinutuzumab) 23.5 MabThera/Rituxan (Rituximab) 23.6 Blinatumomab (Blincyto) 23.7 Lumoxiti (Moxetumomab pasudotox) 23.8 Poteligeo (Mogamulizumab) 23.9 Rituximab Biosimilar (Truxima) 23.10 Rituximab Biosimilar (Ruxience) 23.11 Rituximab Biosimilar (Rixathon) 23.12 Rituximab Biosimilar - Acellbia 23.13 Rituximab Biosimilar - Maball 23.14 Rituximab Biosimilar - Mabtus 23.15 Rituximab Biosimilar - Zytux 23.16 Alemtuzumab (Campath)

24. T-Cell Therapy for Leukemia - Availability, Dosage, & Price Analysis 24.1 Tisagenlecleucel (Kymriah) 24.2 Nalotimagene Carmaleucel (Zalmoxis)

25. Mitotic Inhibitors for Leukemia - Availability, Dosage & Price Analysis 25.1 Vincristine Liposomal (Marqibo)

26. Antineoplastic Interferons for Leukemia - Availability, Dosage & Price Analysis 26.1 Interferon Alpha-2b (Intron A) 26.2 Interferon Alfa-2a (Roferon-A/Veldona) 26.3 Interferon Alpha (Multiferon)

27. Global Leukaemia Drug Clinical Pipeline By Company, Indication & Phase 27.1 Unknown 27.2 Research 27.3 Preclinical 27.4 Clinical 27.5 Phase-0 27.6 Phase-I 27.7 Phase-I/II 27.8 Phase-II 27.9 Phase-II/III 27.10 Phase-III 27.11 Preregistration 27.12 Registered

28. Global Marketed Leukaemia Drug Clinical Insight

29. Global Leukemia Therapeutics Market Dynamics 29.1 Global Leukemia Therapeutics Growth Attributors 29.2 Challenges Concerning the Growth of Leukemia Therapeutics Market at Global Level

30. Global Leukemia Therapeutics Market Future Insights

31. Competitive Landscape 31.1 AbbVie Inc 31.2 Bristol-Myers Squibb 31.3 Amgen 31.4 Genzyme Corporation 31.5 Pfizer 31.6 GlaxoSmithKline Plc 31.7 Novartis International AG 31.8 Teva Pharmaceuticals 31.9 Takeda Pharmaceuticals 31.10 Piramal Pharma Solutions

List of Figures

  • Figure 1-1: Blood Comparison of a Healthy Person & Leukemia Patient
  • Figure 1-2: Major Characteristics of Leukemia Subtypes
  • Figure 1-3: Comparison for Subtypes of Leukemia by Average Age of Diagnosis & 5-Year Survival Percentage
  • Figure 1-4: Contributors to the History of Leukemia
  • Figure 2-1: Available Cancer Treatments for Leukemia in the Market
  • Figure 2-2: Global - Leukemia Death Statistics, 2018
  • Figure 3-1: Cancer Types vs. Leukemia Cancer Treatments
  • Figure 4-1: Treanda - Total Sales (US$ Million), 2016 - 2019
  • Figure 4-2: Tasigna - Total Sales (US$ Million), 2016 - 2019
  • Figure 4-3: Global - Total vs. Active, not Recruiting Chemotherapy Clinical Trials, 2020
  • Figure 4-4: Mechanism of Action of Chemotherapeutic Drugs on Leukemia Cells
  • Figure 5-1: Global - Kymriah Total Sales (US$ Million), 2017 - 2019
  • Figure 5-2: Global - Total vs. Active, not Recruiting Immunotherapy Clinical Trials for Leukemia, 2020
  • Figure 5-3: Outcomes Anticipated by the Arrival of Immunotherapy Treatment for Leukemic Patients
  • Figure 5-4: Mechanism of Action of Immunotherapy on Leukemia Cells
  • Figure 6-1: Properties of Small Molecule Cancer Drugs
  • Figure 6-2: Global - Gleevec Total Sales (US$ Million), 2018 & 2019
  • Figure 6-3: Mechanism of Action of Small Molecule Cancer Drugs on Leukemia Cells
  • Figure 7-1: Global - Total vs. Active, not Recruiting Bone Marrow Transplantation Clinical Trials, 2020
  • Figure 7-2: Global -Bone Marrow Transplantation Market (US$ Billion), 2018 - 2025
  • Figure 7-3: Mechanism of Action of Bone Marrow Transplantation in Leukemia Patients
  • Figure 8-1: Radiation Therapy - Clinical Trials for Leukemia Subtypes, 2020
  • Figure 8-2: Mechanism of Action of Radiation Therapy for Leukemia Patients
  • Figure 11-1: Global - Leukemia Market (US$ Billion), 2019 - 2025
  • Figure 12-1: US - Leukemia Statistics, 2018
  • Figure 12-2: US - Total vs. Active Leukemia Clinical Trials, 2020
  • Figure 12-3: US - Rising Parameters for Leukemia Therapeutics Market
  • Figure 12-4: Europe - Leukemia Statistics, 2018
  • Figure 12-5: Europe - Total Leukemia Clinical Trials, 2020
  • Figure 12-6: Europe - Important Parameters for Leukemia Market Growth
  • Figure 12-7: Asia - Leukemia Statistics, 2018
  • Figure 12-8: China - Total vs. Active, not Recruiting Leukemia Clinical Trials, 2020
  • Figure 12-9: Asia - Parameters Contributing to the Current Leukemia Therapeutics Market Status
  • Figure 13-1: Global - Leukemia Drug Clinical Pipeline by Phase(%), 2019 till 2025
  • Figure 13-2: Global - Leukemia Drug Clinical Pipeline by Phase(Number of Drugs), 2019 till 2025
  • Figure 13-3: Global - Leukemia Drug Clinical Pipeline by Country(Number of Drugs), 2019 till 2025
  • Figure 13-4: Global - Leukemia Drug Clinical Pipeline by Drug Class (Number of Drugs), 2019 till 2025
  • Figure 13-5: Global - Leukemia Drug Clinical Pipeline by Company/Clinic (Number of Drugs), 2019 till 2025
  • Figure 13-6: Global - Leukemia Drug Clinical Pipeline by Patient segment (Number of Drugs), 2019 till 2025
  • Figure 14-1: Vidaza - FDA & First generic Approval Year
  • Figure 14-2: Vidaza - Branded v/s Generic Price for 100mg Intravenous powder (US$), May'2020
  • Figure 14-3: Vidaza - Dose for Initial & Subsequent Treatment Cycle (mg/m2)
  • Figure 14-4: Vidaza - Cost of Initial & Subsequent Treatment Cycle (US$), May'2020
  • Figure 14-5: Venetoclax - Patent Issue & Expiration year
  • Figure 14-6: Venetoclax - Price for Various Supplies of 10mg Tablet (US$), June'2020
  • Figure 14-7: Venetoclax - Price for Various Supplies of 50mg Tablet (US$), June'2020
  • Figure 14-8: Venetoclax - Price for Various Supplies of 50mg Tablet (US$), June'2020
  • Figure 14-9: Venetoclax - Price for 42 Kit & Price per unit Kit (US$), June'2020
  • Figure 14-10: Venetoclax Monotherapy - Recommended Dose by Treatment Week for CLL Management (mg/day), June'2020
  • Figure 14-11: Venetoclax Combinational - Recommended Dose in Initial & Subsequent Treatment Cycle for CLL (mg/Cycle), June'2020
  • Figure 14-12: Venetoclax Monotherapy - Recommended Dose for AML (mg/day), May'2020
  • Figure 14-13: Venclexta - Annual Sales Value (US$ Million), 2017 - 2019
  • Figure 14-14: Venclexta - Annual Sales Value by Region (US$ Million), 2019
  • Figure 14-15: Venclexta - Annual Sales Value by Region (%), 2019
  • Figure 14-16: Global - Venclexta Quarterly Sales Value (US$ Million), 2019
  • Figure 14-17: Idhifa - Patent Issue & Expiration Year
  • Figure 14-18: Idhifa - Price for 30 Tablets & Price per unit of Oral Tablet (US$), June'2020
  • Figure 14-19: Idhifa - Daily & Full Treatment Cost (US$), June'2020
  • Figure 14-20: Idhifa - Annual Sales Value (US$ Million), 2017 & 2018
  • Figure 14-21: Idhifa - US v/s Rest of World Annual Sales Value (US$ Million), 2019
  • Figure 14-22: Idhifa - US v/s Rest of World Annual Sales Value (%), 2019
  • Figure 14-23: Idhifa - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 14-24: Vesanoid - FDA Approval & First Generic Approval Year
  • Figure 14-25: Tretinoin - price for 30 Capsule Supply 7 Price per Unit Capsule (US$), May'2020
  • Figure 14-26: Tretinoin - price for 100 Capsule Supply & Price per Unit Capsule (US$), May'2020
  • Figure 14-27: Tretinoin - Minimum & Maximum Treatment Cost (US$), June'2020
  • Figure 14-28: Ceplene - Europe Market Authorisation & Orphan Designation Year
  • Figure 14-29: Ceplene - Cost of Single Administration, Single Day Treatment & One Treatment Cycle (US$/GBP), June'2020
  • Figure 14-30: Trisenox - FDA Approval Year by Strength
  • Figure 14-31: Trisenox - FDA Approval & First Generic Approval Year
  • Figure 14-32: Arsenic Trioxide - Price for 100ml Supply & Price per ml of Branded & Generic Intravenous Solution of 1mg/ml Dose, June'2020
  • Figure 14-33: Arsenic Trioxide - Price for 60ml Supply & Price per ml of Branded & Generic Intravenous Solution of 2mg/ml Dose (US$), June'2020
  • Figure 14-34: Arsenic Trioxide - Duration of Induction & Consolidation Treatment Cycle (Days)
  • Figure 14-35: Arsenic Trioxide - Number of Required Induction & Consolidation Treatment Cycle
  • Figure 14-36: Amnolake - PMDA Approval & Patent Expiration Year
  • Figure 14-37: Amsacrine - Minimum & Maximum Recommended Dose (mg/m2)
  • Figure 14-38: Immune Globulin - FDA Approval Year by Brand Name
  • Figure 14-39: Cuvitru - Price for 1 & 5 ml Supply of 20% Solution (US$), June'2020
  • Figure 14-40: Cuvitru - Price for 1 & 10 ml Supply of 20% Solution (US$), June'2020
  • Figure 14-41: Cuvitru - Price for 1 & 20 ml Supply of 20% Solution (US$), June'2020
  • Figure 14-42: Cuvitru - Price for 1 & 40 ml Supply of 20% Solution (US$), June'2020
  • Figure 14-43: Cuvitru - Price for 1 & 50 ml of 20% Solution (US$), June'2020
  • Figure 14-44: Gammagard S/D - Price for 5gm and 10gm Powder for Injection (US$), June'2020
  • Figure 14-45: Gammagard Liquid - Price for Various Supplies of Solution (US$), June'2020
  • Figure 14-46: Hyqvia - Price for Various Supplies of Subcutaneous Solution (US$), June'2020
  • Figure 14-47: Immuno Globulin - Minimum & Maximum Duration of Treatment Cycle (Weeks)
  • Figure 14-48: Erwinase - Price for Supply of 5 Powders & Price per unit of 10,000 IU Powder for Injection (US$), June'2020
  • Figure 14-49: Erwinase - Average Cost of Single Administration & Full Treatment Cost (US$), June'2020
  • Figure 14-50: Global - Erwinase Annual sales Value (US$ Million), 2017 - 2019
  • Figure 14-51: Global - Erwinase Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 14-52: Oncaspar - FDA & EMA Approval Year
  • Figure 14-53: Oncaspar - US & Europe Exclusivity Expiration Year
  • Figure 14-54: Oncaspar - Price for 5 ml Supply & Price per ml of Injectable Solution (US$), June'2020
  • Figure 14-55: Oncaspar - Recommended Dose by Age (IU/m2 once in 2 Weeks)
  • Figure 14-56: Asparlas - Price for 1 & 5 mL Solution of Dose 750 units/mL (US$), June'2020
  • Figure 14-57: Oncaspar - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
  • Figure 14-58: Leunase - Price for 10000IU & 5000IU Powder for Injection (INR/US$), June'2020
  • Figure 14-59: Leunase - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$)
  • Figure 15-1: Xospata - Patent Issue Expiration Year
  • Figure 15-2: Xospata - Price for 30 Tablets & Price per unit Tablet (US$), May'2020
  • Figure 15-3: Xospata - Daily, Monthly & Annual Treatment Cost (US$), May'2020
  • Figure 15-4: Global - Xospata Quarterly Sales Value (JPY/US$ Million), 2018 & 2019
  • Figure 16-1: Bosulif - Patent Issue & Expiration Year
  • Figure 16-2: Bosulif - Price for 120 Tablet & Price per Unit of 100mg Tablet (US$), June'2020
  • Figure 16-3: Bosulif - Price for 30 Tablet & Price per Unit of 400 & 500mg Tablet (US$), June'2020
  • Figure 16-4: Bosulif - Recommended Dose for Newly Diagnosed & Therapy Resisted CML (mg)
  • Figure 16-5: Sprycel - FDA Approval Year by Tablet Strength
  • Figure 16-6: Sprycel - Patent Issue & Expiration Year
  • Figure 16-7: Sprycel - Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June'2020
  • Figure 16-8: Sprycel - Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June'2020
  • Figure 16-9: Sprycel - Recommended Dose by Indication (mg/day)
  • Figure 16-10: Sprycel - Recommended Pediatric Dose by Weight (mg/day)
  • Figure 16-11: Iclusig - FDA Approval Year by Tablet Strength (US$), June'2020
  • Figure 16-12: Iclusig - Patent Issue & Expiration Year
  • Figure 16-13: Iclusig - Price for 30 tablets & Price per unit Tablet of 15mg & 45mg (US$), June'2020
  • Figure 16-14: Iclusig - Recommended Initial & Reduced Dose (mg/day)
  • Figure 16-15: Iclusig - Global Sales Value (US$ Million), 2018 & 2019
  • Figure 16-16: Global - Iclusig Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 16-17: Tasigna - FDA Approval Year by Indication
  • Figure 16-18: Tasigna - Patent Issue & Expiration Year
  • Figure 16-19: Tasigna - Price for 120 Capsules & Price per unit Capsule of 50mg (US$), June'2020
  • Figure 16-20: Tasigna - Price for 28 & 112 Capsules & Price per unit Capsule of 100 & 200 mg (US$), June'2020
  • Figure 16-21: Tasigna - Recommended Dose by Indication (mg Twice Daily), June'2020
  • Figure 16-22: Tasigna - Recommended Pediatric Dose by Surface Area (mg Twice Daily), May'2020
  • Figure 16-23: Vanflyta- Recommended Dose for AML Treatment (mg/day)
  • Figure 16-24: Vanflyta- Recommended Dose & Dose after Reduction (mg/day)
  • Figure 16-25: Supect - Daily, Monthly & Annual Treatment Cost (US$), June'2020
  • Figure 16-26: Gleevec - FDA Approval by Dosage Form
  • Figure 16-27: Gleevec - FDA Approval by Indication
  • Figure 16-28: Gleevec - Patent Issue & Expiration Year
  • Figure 16-29: Imatinib - Price for 30 Tablet supply of Branded & Generic Imatinib 400mg (US$), June'2020
  • Figure 16-30: Imatinib - Price for 90 Tablet supply of Branded & Generic Imatinib 400mg (US$), June'2020
  • Figure 16-31: Gleevec - Recommended Dose by Indication (mg/Day)
  • Figure 17-1: Vyxeos - FDA Approval & Patent Expiration Year
  • Figure 17-2: Vyxeos - Price for 1, 2 & 5 Powder for Injection (US$), June'2020
  • Figure 17-3: Vyxeos - Number of Drug Administration Required in Different Treatment Cycles (Dose/Cycle), June'2020
  • Figure 17-4: Tibsovo - FDA Approval Year by Indication
  • Figure 17-5: Tibsovo - Patent Issue & Expiration Year
  • Figure 17-6: Tibsovo - Price for 60 Tablets & Price per unit of 250mg Tablet (US$), May'2020
  • Figure 17-7: Tibsovo - Cost of Daily Treatment & Full Treatment Cost (US$), May'2020
  • Figure 17-8: Global - Tibsovo Sales Value (US$ Million), 2018 & 2019
  • Figure 17-9: Global - Tibsovo Quarterly Sales Value (US$ Million), 2019
  • Figure 17-10: Rituxan Hycela - FDA Approval & Patent Expiration Year
  • Figure 17-11: Rituxan Hycela - Price for 11.7 ml Supply & Price per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), February'2020
  • Figure 17-12: Rituxan Hycela - Price for 13.4 ml Supply & Price per ml of 26,800 units-1,600 mg/13.4ml Subcutaneous Solution (US$), February'2020
  • Figure 17-13: Rituxan Hycela - Duration of CLL Treatment (Weeks), June'2020
  • Figure 17-14: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), June'2020
  • Figure 18-1: Cladribine - FDA Approval Year by Brand Name
  • Figure 18-2: Mavenclad - Merck's Patent Issue & Expiration Year
  • Figure 18-3: Mavenclad - Ares Trading's Patent Issue & Expiration Year
  • Figure 18-4: Mavenclad - Price for various Tablet Supplies of 10mg (US$), June'2020
  • Figure 18-5: Generic Cladribine - Price for 10 & 1ml Intravenous Solution (US$), June'2020
  • Figure 18-6: Cladribine - Recommended Dose by Route of Administration (mg/Kg/day)
  • Figure 18-7: Clolar - FDA Approval & First Generic Approval Year
  • Figure 18-8: Clolar - Price for 20ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 18-9: Generic Clofarabine - Price for 20ml Supply & Price per ml of Intravenous Solution (US$), May'2020
  • Figure 18-10: Clolar - Recommended dose & Dose after Reduction (mg/m2/day)
  • Figure 18-11: Purixan - FDA Approval & Exclusivity Expiration Year
  • Figure 18-12: Purixan - Price for 100ml Supply & Price per ml of Oral Suspension (US$), June'2020
  • Figure 18-13: Purixan - Minimum & Maximum Recommended Dose (mg/Kg)
  • Figure 18-14: Xatmep - Patent Issue & Expiration Year
  • Figure 18-15: Xatmep - Price for 60ml Supply & Price per ml of Oral Solution (US$), June'2020
  • Figure 18-16: Xatmep - Price for 100ml Supply & Price per ml of Oral Solution (US$), June'2020
  • Figure 18-17: Xatmep - Cost of Single Treatment Cycle & Annual Treatment Cost (US$), June'2020
  • Figure 18-18: Decogen - FDA Approval & first Generic Approval Year
  • Figure 18-19: Decitabine - Price for 50mg Branded & Generic Intravenous Powder (US$), June'2020
  • Figure 18-20: Decitabine - Cost of Single Dose, Single day & Single Treatment Cycle using 15mg/m2/Thrice a Day Dose regimen (US$), June'2020
  • Figure 18-21: Decitabine - Cost of Single Day & Single Treatment Cycle using 20mg/m2/Daily Dose regimen (US$), June'2020
  • Figure 18-22: Arranon - FDA Approval Year & Patent Expiration Year
  • Figure 18-23: Arranon - Price for 50ml & 300ml intravenous Solution of 5mg/ml Dose (US$), June'2020
  • Figure 18-24: Arranon - Adult & Pediatric Dose (mg/m2)
  • Figure 18-25: Fludarabin - FDA Approval Year by Brand Name
  • Figure 18-26: Fludarabin - Price for 50mg Intravenous Powder & 2 ml Intravenous Solution for Injection (US$), May'2020
  • Figure 18-27: Methotrexate - Average Price of 10 ml Supply & Price per ml of 25mg/ml Intravenous Solution (US$), June'2020
  • Figure 18-28: Methotrexate - Average Price of Different Supplies of Oral Tablet (US$), June'2020
  • Figure 18-29: Methotrexate - Minimum & Maximum Duration of Initial Treatment Phase of ALL (Weeks), June'2020
  • Figure 18-30: Methotrexate - Single Treatment Cycle Cost in Initial & Maintenance Phase (US$), June'2020
  • Figure 18-31: Methotrexate - Minimum & Maximum Treatment Cost of Initial Phase of ALL (US$), June'2020
  • Figure 18-32: Methotrexate - Duration of Treatment & Rest Period for Choriocarcinoma Treatment (Days), June'2020
  • Figure 18-33: Methotrexate - Minimum & Maximum Treatment Cost of Single Day (US$), June'2020
  • Figure 18-34: Methotrexate - Minimum & Maximum Cost of Single Treatment Cycle (US$), June'2020
  • Figure 19-1: Nipent - FDA Approval & First Generic Approval Year
  • Figure 19-2: Pentostatin - Price for Single Vial of Generic & Branded Pentostatin (US$), May'2020
  • Figure 19-3: Mitoxantron - FDA Approval & First Generic Approval Year
  • Figure 19-4: Mitoxantron - Price for 10ml, 12.5ml & 15 ml Supply of 2mg/ml Intravenous Solution (US$), June 2020
  • Figure 19-5: Mitoxantron - Minimum & Maximum Dose for Prostate Cancer (mg/3weeks)
  • Figure 19-6: Idarubicin - FDA & First Generic Approval Year
  • Figure 19-7: Idarubicine - Price Comparision of 5ml Intravenous Branded & Generic Solution (US$), June'2020
  • Figure 19-8: Idarubicine - Price Comparision of 10ml Intravenous Branded & Generic Solution (US$), June'2020
  • Figure 19-9: Idarubicine - Price Comparision of 20ml Intravenous Branded & Generic Solution (US$), June'2020
  • Figure 19-10: Idarubicin - Dialy & Maximum Cumulative Lifetime Dose (mg/m2), January'2020
  • Figure 19-11: Idarubicin - Comparision of Dialy & Full Treatment Cost uisng Branded & Generic Tablet (US$), January'2020
  • Figure 20-1: Copiktra - Interllikine's Patent Issue & Expiration Year
  • Figure 20-2: Copiktra - Infinity Pharma's Patent Issue & Expiration Year
  • Figure 20-3: Copiktra - Price for 56 Capsules Supply & Price per unit Capsule (US$), June'2020
  • Figure 20-4: Copiktra - Recommended & Reduced Dose (mg/day)
  • Figure 20-5: Zydelig - Number of Patents by Assignee
  • Figure 20-6: Zydelig - Patent Expiration Year by Assignee
  • Figure 20-7: Zydelig - Price for 60 Tablet Supply & Price per Unit Tablet (US$), June'2020
  • Figure 20-8: Zydelig - Recommended & Reduced Dose (mg/day)
  • Figure 20-9: Global - Zydelig Sales Value (US$ Million), 2017 - 2019
  • Figure 20-10: Zydelig - Annual Sales Value by Region (US$ Million), 2019
  • Figure 20-11: Zydelig - Annual Sales Value by Region (%), 2019
  • Figure 20-12: Zydelig - Quarterly Sales Value (US$ Million), 2018 - 2019
  • Figure 21-1: Bendamustine - FDA Approval Year by Brand Name
  • Figure 21-2: Treanda - Patent Issue & Expiration Year
  • Figure 21-3: Bendeka - Number of Patent by Assignee
  • Figure 21-4: Bendeka - Patent Expiration Year by Assignee
  • Figure 21-5: Bendamustine - FDA & First Generic Approval Year
  • Figure 21-6: Bendamustine - Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 21-7: Bendeka - Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 21-8: Belrapzo - Price for 4 ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 21-9: Bendamustine - Comparision of Treatment Cost of CLL uisng Branded & Generic Solution (US$), June'2020
  • Figure 21-10: Cyclophosphamide - FDA Approval Year by Companies
  • Figure 21-11: Cyclophosphamide - Average Price for 1gm, 2gm & 500mg Powder for Injection (US$), June'2020
  • Figure 21-12: Cyclophosphamide - Average Price for a Supply of 100 Capsules of 25mg & 50 mg Dose (US$), June'2020
  • Figure 21-13: Hikma's Cyclophosphamide - Average Price for a Supply of 100 Capsules of 25mg Dose (US$), June'2020
  • Figure 21-14: Cyclophosphamide IV Solution - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June'2020
  • Figure 21-15: Cyclophosphamide Capsule - Minimum & Maximum Treatment Cost of Single Cycle for Average Human (US$), June'2020
  • Figure 22-1: Ibrutinib - FDA Approval Year by Indication
  • Figure 22-2: Ibrutinib - FDA Approval Year by Dosage Form
  • Figure 22-3: Imbruvica - Price for 90 & 120 Capsule Supplies of 140mg (US$), June'2020
  • Figure 22-4: Imbruvica Capsule - Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), June'2020
  • Figure 22-5: Imbruvica Tablet - Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), June'2020
  • Figure 22-6: Imbruvica - Recommended Daily Dose by Indication (mg), May'2020
  • Figure 22-7: Imbruvica - Annual Sales Value (US$ Billion), 2017 - 2019
  • Figure 22-8: Imbruvica - Annual Sales Value by Region (US$ Million), 2019
  • Figure 22-9: Imbruvica - Annual Sales Value by Region (%), 2019
  • Figure 22-10: Global - Imbruvica Quarterly Sales Value (US$ Million), 2019
  • Figure 23-1: Besponsa - Orphan Market Exclusivity Issue & Expiration Year
  • Figure 23-2: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days), June'2020
  • Figure 23-3; Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2), June'2020
  • Figure 23-4: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), June'2020
  • Figure 23-5: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), June'2020
  • Figure 23-6: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks), June'2020
  • Figure 23-7: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
  • Figure 23-8: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
  • Figure 23-9: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), June'2020
  • Figure 23-10: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, June'2020
  • Figure 23-11: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), June'2020
  • Figure 23-12: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2), June'2020
  • Figure 23-13: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), June'2020
  • Figure 23-14: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, June'2020
  • Figure 23-15: Arzerra - Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), June'2020
  • Figure 23-16: Arzerra - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 23-17: Arzerra - Initial & Maintenance Dose for Previously Untreated CLL (mg), June'2020
  • Figure 23-18: Arzerra - Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), June'2020
  • Figure 23-19: Arzerra - Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), June'2020
  • Figure 23-20: Arzerra - Initial & Maintenance Dose for Relapsed CLL (mg), June'2020
  • Figure 23-21: Arzerra - Minimum & Maximum Treatment Cost for Relapsed CLL (US$), June'2020
  • Figure 23-22: Arzerra - Initial & Maintenance Dose for Refractory CLL (mg), June'2020
  • Figure 23-23: Arzerra - Treatment Duration for Refractory CLL (Weeks), June'2020
  • Figure 23-24: Arzerra - Minimum & Maximum Treatment Cost for Refractory CLL (US$), June'2020
  • Figure 23-25: Gazyva - Approval Year by Non-Hodgkin's Lymphoma Type
  • Figure 23-26: Gazyva - Price for 40ml Supply & Price per ml of Intravenous Solution (US$), June'2020
  • Figure 23-27: Gazyva - Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), June'2020
  • Figure 23-28: Gazyva - Duration of Single Treatment Cycle & Full Treatment of CLL (Week), June'2020
  • Figure 23-29: Gazyva - Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), June'2020
  • Figure 23-30: Gazyva - Annual Sales Value (US$/CHF Million), 2016 - 2019
  • Figure 23-31: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2018
  • Figure 23-32: Global - Gazyva Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 23-33: US - Gazyva Quarterly Sales Value (US$ Million), 2019
  • Figure 23-34: Gazyva - Annual Sales Value by Region (CHF/US$ Million), 2019
  • Figure 23-35: Gazyva - Annual Sales Value by Region (%), 2019
  • Figure 23-36: Gazyva - FDA Approval Year by Indication
  • Figure 23-37: Rituxan - Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June'2020
  • Figure 23-38: Rituxan - Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June'2020
  • Figure 23-39: Rituxan - Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), June'2020
  • Figure 23-40: Rituxan - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-41: Rituxan - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-42: Rituxan - Annual Sales Value (US$/CHF Billion), 2017 - 2019
  • Figure 23-43: Global - Rituxan Quarterly Sales Value (US$ Billion), 2018 & 2019
  • Figure 23-44: US - Rituxan Quarterly Sales Value (US$/CHF Billion), 2019
  • Figure 23-45: Rituxan - Annual Sales Share of US & Rest of World (%), 2019
  • Figure 23-46: Rituxan - Annual Sales Value by Region (CHF/US$ Billion)), 2019
  • Figure 23-47: Rituxan - Annual Sales Value by Region (%), 2019
  • Figure 23-48: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, June'2020
  • Figure 23-49: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days), June'2020
  • Figure 23-50: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), June'2020
  • Figure 23-51: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, June'2020
  • Figure 23-52: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), June'2020
  • Figure 23-53: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), June'2020
  • Figure 23-54: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), June'2020
  • Figure 23-55: Global - Blincyto Sales Value (US$ Million), 2016 - 2019
  • Figure 23-56: Blincyto - Sales Value by Region (US$ Million), 2019
  • Figure 23-57: Blincyto - Sales Value by Region (%), 2019
  • Figure 23-58: Blincyto - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 23-59: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 23-60: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), June'2020
  • Figure 23-61: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), June'2020
  • Figure 23-62: Poteligeo - FDA Approval & Patent Expiration Year
  • Figure 23-63: Poteligeo - Price for 5ml Supply & Price per unit of 4mg/ml Intravenous Solution (US$), June'2020
  • Figure 23-64: Poteligeo - Number of Dose Administration in Initial & Subsequent Treatment Cycle
  • Figure 23-65: Poteligeo - Cost of Single Dose, Initial & Subsequent Treatment Cycle (US$), June'2020
  • Figure 23-66: Japan - Poteligeo Sales Value (US$ Million), 2018 & 2019
  • Figure 23-67: Global - Poteligeo Sales Value (US$ Million), 2018 & 2019
  • Figure 23-68: Japan - Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
  • Figure 23-69: ROW - Poteligeo Quarterly Sales Value (JPY/US$ Million), 2019
  • Figure 23-70: Truxima - Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), June'2020
  • Figure 23-71: Truxima - Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), June'2020
  • Figure 23-72: Truxima - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-73: Truxima - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-74: Ruxience - Price for 1 & 10 mL Solution of Dose 10 mg/mL (US$), June'2020
  • Figure 23-75: Ruxience - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-76: Ruxience - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-77: Rixathon - Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (GBP/US$), June'2020
  • Figure 23-78: Rixathon - Price for Supply of 2 Vials & Price per unit Vial of 50ml Solution (GBP/US$), June'2020
  • Figure 23-79: Rixathon - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-80: Ruxience - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-81: Acellbia - Price for Supply of 2 Vials & Price per unit Vial of 10ml Solution (INR/US$), June'2020
  • Figure 23-82: Acellbia - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-83: Acellbia - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-84: Maball - Price for Supply of 10ml & Price per ml of Injection (INR/US$), June'2020
  • Figure 23-85: Maball - Price for Supply of 50ml & Price per ml of Injection (INR/US$), June'2020
  • Figure 23-86: Acellbia - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-87: Acellbia - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-88: Mabtus - Price for Supply of 10ml & Price per ml of Injection (INR/US$), June'2020
  • Figure 23-89: Mabtus - Price for Supply of 50ml & Price per ml of Injection (INR/US$), June'2020
  • Figure 23-90: Mabtus - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-91: Mabtus - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-92: Zytux - Price for Supply of 2 Vail & Price per unit Vial of 10ml solution for Injection (LL/US$), June'2020
  • Figure 23-93: Zytux - Average Cost of Initial & Subsequent Treatment Cycle for CLL Treatment (US$), June'2020
  • Figure 23-94: Zytux - Duration of Single Treatment Cycle & Full Treatment of CLL (Weeks), June'2020
  • Figure 23-95: Campath - FDA Approval Year by Brand Name
  • Figure 23-96: Campath - Cost of Single Dose & Single Treatment Cycle (US$), June'2020
  • Figure 24-1: Kymriah - FDA approval Year by Cancer Type
  • Figure 24-2: Kymriah - Number of Patents in US, Europe & Japan
  • Figure 24-3: Kymriah - Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000'), June'2020
  • Figure 24-4: Kymriah - Sales Value (US$ Million), 2017 - 2019
  • Figure 24-5: Kymriah - Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 24-6: Synribo - Patent Issue & Expiration Year
  • Figure 24-7: Synribo - Treatment Phase in Induction & Maintenance Cycle (Weeks/Cycle)
  • Figure 24-8: Zalmoxis - Orphan Drug Designation & European Approval Year
  • Figure 24-9: Zalmoxis - Cost of Single Treatment Cycle & Full Treatment (EUR/US$), June'2020
  • Figure 25-1: Marqibo - FDA Approval & Patent Expiration Year
  • Figure 25-2: Marqibo - Recommended Dose & Dose after Reduction (mg/m2 Once Weekly)
  • Figure 26-1: Intron A - Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), June'2020
  • Figure 26-2: Intron A - Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), June'2020
  • Figure 26-3: Intron A - Average Cost of Single Treatment Cycle for Hairy Cell Leukemia by Dosage Forms (US$), June'2020
  • Figure 26-4: Intron A - Average Cost of Full Treatment of Course Hairy Cell Leukemia by Dosage Forms (US$), June'2020
  • Figure 26-5: Roferon-A - Price for a Supply of 3 Million IU & 4.5 Million IU Syringe (INR/US$), June'2020
  • Figure 26-6: Roferon-A - Recommended Dose by Type of Leukemia (Million IU/ Day)
  • Figure 29-1: Drivers for Leukemia Therapeutics Market Growth